Keeping Acne Under Control After Isotretinoin

By Michael Wiederkehr, M.D.

Finishing isotretinoin is a treatment milestone, but it does not mean that every future spot represents failure. Some people remain clear, some have occasional mild lesions, and some need further treatment. These are different outcomes, and the plan after the course should recognize that range.

Maintenance means preserving a response after successful initial treatment. It is different from treating acne that never became adequately controlled, and different again from deciding whether a second isotretinoin course is appropriate. Confusing these stages can lead to unnecessary alarm or delayed care.

A maintenance systematic review and supplementary methods describing isotretinoin retreatment provide useful context for care after a successful course. These documents are particularly useful because they reveal how researchers define success, relapse, and a repeat course. Further primary studies and current guidelines provide context for practical follow-up.

This article focuses on the period after treatment: how to understand recurrence, compare maintenance options, build a tolerable routine, and know when reassessment is needed. It does not provide a personal prescription. The dose decisions during the initial course are addressed separately in this series.

Define the starting point before choosing maintenance

The first question is whether the initial acne response was satisfactory. If active disease remains substantial, the next decision may be continued treatment or a revised treatment strategy rather than maintenance. The word should describe the actual stage of care.

A useful end-of-course review records what has improved, what remains active, what adverse effects persist, and what the clinician recommends next. It can distinguish new lesions from residual redness, dark marks, and established scars. Those findings may coexist, but they do not require identical management.

The table prevents a common misunderstanding: a patient looks at skin that is not visually perfect and concludes the course did not work. Improvement in active acne, residual changes, and treatment burden need to be assessed separately.

A plan should also explain what level of control is realistic. Promising never to have another spot creates an unnecessary all-or-nothing standard that research does not support for every patient.

A spot, a relapse, and a repeat course are not interchangeable

Research definitions of relapse vary. Some studies count a rise in lesion number, some use a clinical severity threshold, and others identify a new prescription. A repeat isotretinoin course is a narrower treatment event than every possible recurrence.

A person can have a few mild lesions without needing systemic treatment. Another may have recurrence treated with a topical medicine. A third may need an oral treatment. Only some will receive isotretinoin again. These outcomes should not be collapsed into a single rate of "failure."

An invented example makes the distinction clear. In a group of 100 people, imagine that 25 notice new lesions, 15 seek care, ten receive prescription treatment, and four begin isotretinoin again. Depending on the definition, a report could describe 25%, 10%, or 4%. None is the universal relapse rate; each counts a different event.

This is why a clinician may answer "Will it come back?" by asking what the patient means by "it." Is the concern any spot, a return of painful nodules, scarring, another prescription, or another prolonged course? Naming the feared outcome makes the conversation more useful.

It also helps emotionally. A single lesion after months of treatment can feel like proof that the entire process was pointless. A written plan can put that event in context and establish when to observe, when to contact the clinic, and when reassessment is needed.

What the large claims study measured

A 2025 cohort study included 19,907 patients with at least four months of isotretinoin and suitable follow-up in a commercial claims database. It reported 22.5% with a defined relapse and 8.2% with isotretinoin retrial. Relapse was identified through subsequent systemic acne prescriptions, not every minor breakout. ^[1]

Those figures are useful, but they should not be described as the percentage of patients whose skin was never clear again. The database captures treatment and healthcare use under specified rules. It cannot observe every lesion in every person outside a consultation.

The study found associations between cumulative exposure and subsequent outcomes. It did not randomly assign treatment duration or dose, and patient weight was estimated using population reference information rather than measured individually. ^[1] These features limit causal and individual dosing conclusions.

For the maintenance discussion, the most useful point is the difference between relapse and retrial. More patients received some subsequent systemic treatment than received another isotretinoin course. Recurrence therefore does not imply a single inevitable next step.

An article should also retain the study population. People with commercial insurance and documented follow-up are not automatically representative of every healthcare setting. Access, prescribing patterns, and enrollment requirements influence which events appear in claims data.

The study helps set expectations, but it cannot calculate one reader's exact probability. That requires a clinical discussion informed by the person's acne pattern, prior response, and available options.

What the external validation supplement counted

An external validation supplement provides additional information using Weill Cornell electronic records. It defined an apparent completed course through two isotretinoin exposures five to eight months apart. A repeat exposure was counted more than one and up to five years after the second exposure. Among 1,564 included patients, 188 had additional prescriptions, or 12%. ^[2]

The word "apparent" is important. Prescription records provide a practical way to identify a likely course, but they do not directly document every capsule taken or every clinical reason for stopping. The operational definition makes the analysis possible while creating limits.

The 12% figure should not be compared casually with the claims study's 8.2% as if one disproves the other. The populations, eligibility rules, event definitions, and time windows differ. A longer or differently positioned observation window can count different events.

This comparison is the kind of detail a supplementary document adds. It helps explain variation without inventing a biological difference that the studies did not establish.

What the maintenance review found

The 2016 systematic review identified five randomized trials and three nonrandomized studies across several maintenance approaches. Adapalene and adapalene-benzoyl peroxide were among the studied options, but the evidence was limited and outcomes varied. Not every study concerned patients finishing isotretinoin. ^[3]

The supplementary methods define maintenance after successful induction treatment and list study selection details. ^[4] That distinction matters: evidence following one initial treatment should not automatically be labeled evidence specifically after isotretinoin.

A review can support a maintenance strategy while still leaving uncertainty about the best option for every patient. Differences in induction treatment, follow-up, relapse definitions, and tolerability affect how studies can be combined and applied.

The correct conclusion is therefore neither "maintenance has no evidence" nor "everyone needs the same maintenance product forever." The evidence supports considering appropriate topical strategies, while the choice and duration require individual assessment and review.

A useful reading habit is to ask two questions of every maintenance paper: "What treatment created the initial response?" and "What counted as losing it?" Without those answers, the label "maintenance trial" is incomplete.

This also explains why a general acne guideline and a post-isotretinoin trial serve different roles. The guideline integrates a broader treatment literature. The specific trial may match the immediate question more closely but include fewer people or weaker comparison methods. Both need to be read at their actual level of certainty.

Evidence specifically after isotretinoin

A 2013 study evaluated a 12-month adapalene-benzoyl peroxide maintenance regimen after oral isotretinoin. ^[5] Its direct relevance to the post-course setting makes it worth considering, but its design should not be mistaken for a large blinded randomized comparison establishing a universal regimen.

A separate randomized trial studied maintenance after a successful preceding acne treatment and found benefit from adapalene-benzoyl peroxide compared with vehicle over six months. ^[6] That supports the maintenance concept, while the preceding treatment and eligibility determine how directly it applies after isotretinoin.

These distinctions are more useful than assembling a list of favorable percentages. A study that most closely matches the patient's situation may have a smaller sample. A larger trial may address a related but different pathway. The clinician combines relevance and strength rather than choosing only one.

Patients can ask: "Is this recommendation based specifically on people after isotretinoin, or on maintenance acne evidence more broadly?" Either answer can be reasonable if stated honestly. The question helps prevent overclaiming without dismissing useful indirect evidence.

The expected benefit should also be described as risk reduction or preservation of control, not a guarantee. A person can use an appropriate maintenance treatment and still develop recurrence. That does not necessarily mean the treatment had no effect; the counterfactual course without it is unknown for that individual.

What guidelines recommend and what they leave open

NICE states that maintenance is not always necessary. It suggests considering it for people with a history of frequent relapse, using adapalene-benzoyl peroxide as an option and considering individual topical alternatives when the combination is unsuitable. It recommends reviewing maintenance after 12 weeks. ^[7]

The AAD guideline describes topical therapies as important for initial and maintenance acne care, with combinations chosen according to the treatment context. It also emphasizes limiting systemic antibiotic use and avoiding topical antibiotic monotherapy. ^[8]

These recommendations provide a framework, not a personal prescription. They do not mean every patient should start multiple products immediately after the last capsule. Current skin tolerance, pregnancy considerations, contraindications, and the actual recurrence pattern affect the plan.

The review point is especially important. Maintenance should be an active decision with a purpose, not an old prescription that continues indefinitely because nobody revisits it.

Topical retinoids: a different exposure from oral isotretinoin

A topical retinoid and oral isotretinoin belong to a related therapeutic family but are not the same treatment. Route, exposure, indication, tolerability, and safety instructions differ. Finishing the oral course does not automatically establish which topical product should follow or how it should be introduced.

AAD patient guidance explains that topical retinoids may be recommended for maintenance. ^[9] The clinician should specify the product, application instructions, start timing, and response to irritation. A patient should not assume that a previous routine is appropriate immediately after the course without reviewing current skin condition.

The practical goal is a regimen that can actually be used. A theoretically effective product provides little benefit if the patient repeatedly stops because of discomfort or uncertainty. Discussing tolerability early can prevent a cycle of overuse, irritation, abandonment, and later escalation.

A clear instruction should answer what area to treat, how often to apply the product, what accompanying skin care is appropriate, and when to ask for help. These details are product- and patient-specific, so a general article should not invent a universal schedule.

Pregnancy planning is another reason to obtain explicit advice. Safety instructions for topical and oral retinoids are not interchangeable, and a maintenance plan should be reviewed if pregnancy is possible or planned. Do not infer that a product is suitable simply because it is applied to the skin.

Benzoyl peroxide, azelaic acid, and combination choices

NICE includes benzoyl peroxide and azelaic acid among possible individual maintenance options when an adapalene-benzoyl peroxide combination is unsuitable. ^[7] The choice depends on contraindications, tolerability, clinical features, and the person's preferences.

A combination product can simplify a routine by putting two active ingredients into one application. It can also be unsuitable if one component causes a problem. A single-agent option is not automatically weaker in the context that matters: a treatment that is appropriate and consistently tolerated may be preferable to an abandoned combination.

The table is a decision aid rather than a ranking. It does not imply equal evidence for every option after isotretinoin. The clinician should explain whether the recommendation rests on direct post-course evidence, broader maintenance research, or individual considerations.

Patients should also check the active ingredients in nonprescription products. A cleanser, serum, and spot treatment can duplicate exposures without the person realizing it. The relevant comparison is the whole routine, not only the named prescription.

Why antibiotics are not an automatic long-term maintenance answer

Antibiotics have a role in selected acne treatment, but guidelines emphasize limiting systemic use and combining antibiotic treatment with appropriate nonantibiotic measures. ^[8] A new prescription after isotretinoin should have a defined purpose rather than become indefinite treatment by default.

The question is not whether antibiotics are always wrong. It is whether the patient currently needs an antibiotic, what outcome is expected, how long the plan lasts, and what treatment follows. Those questions support responsible use without undermining a justified prescription.

A person should not restart leftover oral antibiotics when a few lesions appear. The current diagnosis, medicine history, contraindications, and treatment interactions need review. Leftover medication also represents an incomplete plan: there may be no adequate duration, follow-up, or maintenance strategy.

The timing around isotretinoin matters. Product information warns against concomitant tetracycline use. ^[10] A patient should tell the clinician about a recent course rather than assume that different services have access to the same prescription record.

A useful follow-up question is: "If this treatment controls the flare, what is the plan to keep control afterward?" That keeps the distinction between active treatment and maintenance visible. It also reduces the chance of a person repeatedly receiving short disconnected courses without an overall strategy.

Skin care should support the plan rather than compete with it

AAD advice favors gentle cleansing, avoiding abrasive handling, and using appropriate sun protection. ^[11] These measures support care but should not be advertised as a guaranteed substitute for medical maintenance when it is indicated.

After a demanding oral course, some patients feel they must begin an intensive routine to protect the result. They add exfoliating acids, scrubs, multiple serums, spot treatments, and stronger cleansers at once. If irritation follows, it becomes difficult to know which exposure mattered.

A simpler routine is easier to assess. The clinician can identify the essential treatment and supportive products, then review tolerance before additional changes. This is a practical reasoning principle rather than evidence that every complex routine is harmful.

The routine should remain affordable and realistic. A plan requiring products the person cannot obtain or steps they cannot sustain is unlikely to work as intended. Discuss these constraints openly rather than treating inconsistent use as a personal failure.

The goal is control with tolerable care, not a perfect shelf of products.

Adherence problems often reveal a design problem

If a patient does not use maintenance treatment consistently, ask why before assuming they are uninterested. The product may irritate, bleach fabrics, feel unpleasant, cost too much, or conflict with a daily routine. Instructions may be vague or misunderstood.

Each barrier points toward a different solution. Irritation needs a tolerability discussion. Cost needs an accessible alternative. Confusing instructions need clarification. A person who forgets an unnecessary midday step may need a simpler regimen rather than another reminder application.

A useful review separates intended use from actual use. "I was prescribed this nightly, but I used it twice last week because of burning" provides more information than "I used the treatment." The clinician can interpret the response only if the actual exposure is known.

This should be a nonjudgmental conversation. If patients expect criticism, they may report ideal use and leave with an escalation based on inaccurate information. Honest descriptions support a more effective plan.

The same reasoning applies when the product works well. A successful regimen should not be complicated automatically because a new product becomes available. Changes should address a defined need rather than the assumption that more treatment must produce more protection.

Maintenance is often a long enough process that convenience matters clinically. The best plan on paper is not necessarily the best plan in a person's bathroom, budget, workplace, and daily schedule.

Returning oiliness does not by itself define relapse

A person may notice that skin feels less dry or more oily after treatment and become anxious that acne is returning. Oiliness is an observation worth discussing, but it is not identical to a documented return of inflammatory acne.

The practical assessment should focus on the actual lesions and their pattern. Are new comedones appearing? Are inflammatory spots becoming more frequent? Are there painful deeper lesions or new scars? Has the concern persisted or changed over time?

This does not mean waiting until disease becomes severe. It means using a more meaningful threshold than a single sensation of oiliness. The end-of-course plan can define what should prompt contact before the patient is distressed by uncertainty.

Overreacting to oiliness by harsh cleansing can create another problem without answering the recurrence question. AAD advice on oily skin still favors appropriate gentle care and suitable products rather than aggressive washing. ^[12]

An illustrative record might note: "More oiliness this month, two mild lesions, no deep lesions, current topical used as instructed." That is a clearer basis for review than "Everything is back." If the pattern changes, the record can show it.

The clinician can then decide whether the current plan is adequate, whether maintenance should be introduced or adjusted, or whether a new assessment is needed. A single feature should not carry the entire treatment decision.

When recurrent acne deserves earlier review

A return of painful deep lesions, new scarring, a substantial increase in inflammatory acne, or a major effect on well-being deserves timely contact. The patient should not feel required to wait until the condition matches its worst pre-treatment state before asking for help.

At the same time, the response need not be predetermined. Reassessment can identify the current severity, check the diagnosis, review previous treatment and actual maintenance use, and discuss options. A second isotretinoin course is one possible pathway, not the automatic meaning of the word "relapse."

Patients should describe change over time rather than only the worst day. Photographs under similar conditions can support the account if the clinic requests them. The images should supplement the history rather than become a daily score of self-worth.

A useful return plan answers:

1. Which changes should prompt contact?
2. Which service should be contacted?
3. How soon should the review occur?
4. What should continue while waiting?
5. What should not be restarted independently?
6. What information should be brought to the appointment?

If the original clinician is no longer available, a concise course summary becomes particularly useful. It can include the product, approximate dates, reasons for stopping, response, important adverse effects, and the maintenance plan. The new clinician should not have to reconstruct the entire course from memory alone.

A second course is a new prescribing decision

Current product information notes that acne can continue to improve after a course and recommends a waiting period before considering another course. ^[10] The exact decision requires reassessment rather than immediately using leftover capsules or repeating an old prescription.

A second course needs a fresh review of indication, current health, medicines, previous adverse effects, pregnancy prevention requirements where applicable, and monitoring. A prior successful course does not remove those responsibilities.

The clinician should also consider what the recurrence looks like now. The disease may be less severe or have a different distribution. A treatment appropriate for the original presentation may not be the most proportionate next step.

This is another reason research retrial rates should not be read as treatment instructions. A database can show that a prescription occurred. It does not necessarily reveal the full shared decision, the alternatives considered, or the patient's preferences.

For the patient, the useful questions concern the goal and tradeoffs: "What benefit would another course offer compared with the alternatives?" "How did the previous course affect the plan?" "What will we do afterward to reduce the chance of another disconnected cycle?"

A repeat course is neither automatically a failure nor automatically the best answer. It is a treatment option that needs the same careful reasoning as any consequential prescription.

Hormonal patterns and other contributors require assessment

Some patients notice a recurring distribution or timing pattern and wonder whether another contributor should be investigated. The clinician can consider the history and examination rather than assuming all post-course recurrence has the same explanation.

A pattern alone does not establish a hormonal diagnosis. It can guide questions about other symptoms, medication changes, and relevant medical history. Testing should answer a clinical question rather than become a broad panel ordered solely because a treatment course has ended.

The AAD guideline includes hormonal treatment options for appropriate patients. ^[8] Their suitability depends on individual circumstances and should not be inferred from sex alone or from an internet description of "hormonal acne."

Patients should bring a current medication list, including supplements and medicines prescribed for other conditions. A new exposure may matter to the differential diagnosis or the choice of treatment even if it is not the main cause of the acne.

The important principle is to keep the assessment open. Calling every recurrence an inadequate cumulative dose can obscure other contributors. Calling every lower-face lesion hormonal can do the same. A useful clinical explanation connects the actual findings to a justified treatment choice.

This article does not propose a universal laboratory workup after isotretinoin. It supports targeted questions when the pattern or associated symptoms give the clinician a reason to investigate further.

Pregnancy planning changes the maintenance conversation

The end of an oral course does not mean every safety instruction ends on the day of the last capsule. Patients should follow the current product-specific and local requirements, including the post-treatment pregnancy precautions that apply to isotretinoin. ^[10]

Maintenance products also need review when pregnancy is possible or planned. Do not assume that a topical medicine is suitable because it is not taken by mouth. The prescriber should identify an appropriate plan and explain any restrictions.

The practical step is to raise pregnancy planning before starting or continuing maintenance, rather than waiting for a routine refill. This allows the clinician to review the whole regimen, including nonprescription products.

The same approach applies when another clinician becomes involved. Provide the recent isotretinoin history and the exact topical names. A general statement such as "I finished acne tablets" may omit information needed for safe advice.

No article should manufacture a personal clearance date without the actual treatment dates and current instructions. A clear written plan is preferable to calculating a timeline from an old forum post or another country's process.

This is a focused medication-planning issue, not a reason to add unrelated warnings to every skin-care decision. The aim is to ensure that the products used to preserve acne control remain appropriate for the patient's changing circumstances.

Four examples of proportionate follow-up

Occasional mild lesions after a good response

A hypothetical person has a few scattered lesions but remains much improved and has no new scarring. The clinician can review whether observation or a suitable topical plan is appropriate. The event does not automatically mean a second oral course is needed.

A maintenance product that is not tolerated

Another patient stops a prescribed topical because of persistent irritation. The useful response is to review the actual product, instructions, and skin condition. Calling the patient nonadherent without examining the barrier leaves the problem unresolved.

Increasing deep lesions and new scars

A third person notices a progressive return of painful lesions. This deserves timely reassessment rather than indefinite self-treatment. The next option depends on the current presentation and previous course, not a generic rule that all recurrence is mild.

Anxiety about a single spot

A fourth person feels distressed by one lesion after a difficult course. The concern should be treated respectfully while the clinician explains the difference between an isolated lesion and a pattern requiring further treatment. A return plan can reduce the need to interpret every day independently.

These scenarios are illustrative. Their purpose is to show that the same phrase, "acne came back," can describe different situations. Proportionate care responds to the actual pattern and burden rather than to the label alone.

Frequently asked questions

Build a written plan before care becomes fragmented

An end-of-course plan can fit on a page. It should state whether maintenance is recommended, the exact products and instructions, the planned review, and the signs that should prompt earlier contact. It should also distinguish acne care from follow-up of any persistent adverse effects.

The plan is particularly helpful when the prescribing service and future follow-up service differ. Without a summary, patients may receive duplicate products, conflicting instructions, or repeated treatment courses without continuity. A concise record helps the next clinician understand what has already been tried.

The plan should describe uncertainty honestly. If observation is appropriate, say what is being observed and what would change the decision. If maintenance is recommended, say what benefit is expected and how tolerance will be assessed. If another course may be considered later, identify the reason for reassessment rather than presenting it as inevitable.

Patients can then focus on ordinary use of the agreed routine instead of repeatedly searching for the one product that guarantees permanent clearance. No study provides that guarantee for every person. What the evidence does support is a clearer separation of response, maintenance, recurrence, and retreatment.

That separation makes follow-up more proportionate. It allows a mild recurrence to receive a mild response when appropriate, while preserving timely care for significant disease. The result of the first course becomes the starting point for a durable plan rather than an event that is judged successful or unsuccessful by the next isolated spot.

Three ways of defining success change the maintenance decision

Consider three hypothetical patients who all describe their treatment as successful. The first has no new lesions and wants to minimize future treatment burden. The second has occasional mild lesions but is satisfied because painful nodules have stopped. The third looks much clearer but still develops new scars. These situations should not be managed as identical simply because each patient uses the word "success."

For the first person, the conversation may center on whether any maintenance is needed and how to recognize a meaningful change. For the second, it may center on preserving acceptable control with a tolerable topical plan. For the third, the clinician needs to assess whether active disease remains insufficiently controlled. Calling that situation maintenance could delay an appropriate response.

The same distinction applies to research. A trial that requires a specified level of improvement before randomization starts with a selected population. Its maintenance result applies most directly to people who reached that entry threshold. It cannot answer what the same treatment would do for people who never achieved adequate initial control.

A patient-centered goal therefore needs two parts: the clinical target and the treatment burden the person is willing and able to accept. A regimen that produces slightly fewer lesions but causes persistent discomfort may not represent the best balance for that person. A regimen that is easy to use but leaves new scars also needs reassessment. Both benefit and burden belong in the review.

The review should also account for time. A week with no lesions is not equivalent to sustained control over several months. Conversely, one difficult week does not necessarily describe the entire post-course trajectory. Looking at a reasonable interval helps prevent decisions based only on the most recent day.

A practical review can ask the patient to describe the preceding period in three sentences: what happened to active lesions, what happened to tolerance, and what happened to normal activities. That short account often reveals more than an unqualified answer to "Is your skin better?" It can also show whether the maintenance plan is addressing the concern that originally mattered.

If expectations differ between patient and clinician, make them explicit. The patient may be trying to prevent any visible lesion while the clinician is aiming to prevent inflammatory recurrence and scarring. Neither goal should be assumed silently. Agreement on the target makes later decisions more understandable and reduces frustration when a treatment performs well on one outcome but not another.

Finally, a maintenance decision should be revisable. Continuing, simplifying, changing, or stopping a plan can each be appropriate after assessment. The existence of an old prescription is not evidence that it remains necessary. The absence of a current prescription is not evidence that the patient should wait indefinitely if disease returns. A useful plan preserves both flexibility and a clear route back to care.

Keep the agreed review date even when the routine appears straightforward.

What to keep in an end-of-course record

A useful course summary should include the approximate treatment dates, the main response, important adverse effects, and the clinician's instructions for what comes next. If the plan includes a topical product, record its exact name and intended use rather than only the brand family. That information helps another clinician understand what was actually recommended.

Keep the return instructions with that summary. The patient should know which change warrants contact, which service will review it, and what to continue while waiting. If the prescribing clinic and follow-up clinic differ, share the summary through their usual process. The aim is continuity: a later flare should be assessed with knowledge of the successful treatment, its limitations, and the maintenance approach already tried.

References

1. Lai J, Barbieri JS. Acne Relapse and Isotretinoin Retrial in Patients With Acne. JAMA Dermatology. 2025. https://jamanetwork.com/journals/jamadermatology/fullarticle/2829255
2. Supplemental Methods and Results for Systemic comorbidities associated with oral isotretinoin retrial among patients with acne. https://data.mendeley.com/datasets/d585c85f7z/1
3. How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy. 2016. https://pubmed.ncbi.nlm.nih.gov/27220773/
4. Supplementary maintenance review methods and excluded studies. https://figshare.com/articles/dataset/3995757
5. Maintenance therapy for acne vulgaris: efficacy of a 12-month treatment with adapalene-benzoyl peroxide after oral isotretinoin and a review of the literature. 2013. https://pubmed.ncbi.nlm.nih.gov/24029411/
6. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. 2011. https://pubmed.ncbi.nlm.nih.gov/21457209/
7. NICE. Acne vulgaris: management, maintenance recommendations. https://www.nice.org.uk/guidance/ng198/chapter/Recommendations
8. AAD. Guidelines of care for the management of acne vulgaris. 2024. https://pubmed.ncbi.nlm.nih.gov/38300170/
9. AAD. Acne: Diagnosis and treatment. https://www.aad.org/public/diseases/acne/derm-treat/treat
10. Isotretinoin capsules prescribing information, revised August 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cf11710-f966-4529-8e08-02175f588bca
11. AAD. Acne: Tips for managing. https://www.aad.org/public/diseases/acne/skin-care/tips
12. AAD. How to control oily skin. https://www.aad.org/public/everyday-care/skin-care-basics/dry/oily-skin